PXD#

Related by string. * * *

Related by context. All words. (Click for frequent words.) 76 MGCD# [001] 76 enzastaurin 76 ganetespib 75 HGS ETR1 75 OXi# 75 alvespimycin 74 INCB# [001] 74 axitinib 74 RGB # 73 CR# vcMMAE 73 PEG SN# 73 oral prodrug 73 pomalidomide 73 HGS ETR2 73 mapatumumab 72 CA4P 72 forodesine 72 AP# [003] 72 anti leukemic 72 obatoclax 72 elotuzumab 72 lintuzumab 72 cilengitide 72 Phase Ib 72 vidofludimus 72 tanespimycin 72 imetelstat 71 velafermin 71 HGS# 71 GRN#L 71 eniluracil 71 TACI Ig 71 belinostat 71 velafermin belinostat 71 Imprime PGG 71 Azedra 71 APOPTONE 71 neratinib 71 MEK inhibitors 71 elesclomol 71 XmAb# 71 HuMax EGFr 71 decitabine 71 IMC A# 71 depsipeptide 71 BAY #-# 71 Sym# 71 Symadex 71 Bortezomib 70 Carfilzomib 70 CYT# 70 otelixizumab 70 AEG# 70 NGX# 70 dacetuzumab 70 MAGE A3 ASCI 70 YONDELIS 70 perifosine 70 Phase 2a trial 70 MyVax R 70 Atiprimod 70 Phase Ib study 70 Virulizin ® 70 voreloxin 70 cediranib 70 JAK inhibitors 70 XL# [003] 70 MEK inhibitor RDEA# 70 HuMax CD# 70 JAK inhibitor 70 CYC# 70 Traficet EN 70 epigenetic therapies 70 Xanafide 70 HCD# [002] 70 phase IIb clinical 70 Bicifadine 70 HER2 positive metastatic breast 69 INCB# [002] 69 AQ4N 69 IMA# 69 erlotinib Tarceva ® 69 R#/MEM # 69 ofatumumab 69 pertuzumab 69 ENMD # 69 ASONEP 69 LY# [003] 69 Perifosine 69 OncoVEX GM CSF 69 preclinically 69 deforolimus 69 Tyrima 69 sapacitabine 69 IMGN# 69 tezampanel 69 REOLYSIN ® 69 MGd 69 PKC# 69 romidepsin 69 Targretin 69 IAP inhibitors 69 milatuzumab 69 pralatrexate 69 Panzem R NCD 69 anticancer agent 69 MEK inhibitor 69 entinostat 69 talactoferrin 68 GALNS 68 BRAF inhibitor 68 favorable pharmacokinetic profile 68 SAR# [004] 68 Triolex 68 riociguat 68 tesmilifene 68 Debio 68 Golimumab 68 CRLX# 68 TRIOLEX 68 Archexin 68 Phase Ib clinical 68 Dacogen injection 68 Phase 1b trial 68 seliciclib 68 HuLuc# 68 mTOR inhibitors 68 FOLOTYN ® 68 Cloretazine R VNP#M 68 zanolimumab 68 PEG Interferon lambda 68 HuMax CD4 68 PRT# 68 phase Ib 68 Epratuzumab 68 GSK # 68 elacytarabine 68 Romidepsin 68 CCX# 68 atacicept 68 vascular disrupting agent 68 ELACYT 68 Pralatrexate 68 galiximab 68 antitumor 68 eltrombopag 68 vascular disrupting agents 68 TRO# 68 CBLC# 68 valopicitabine 68 Exelixis compounds 68 Neuradiab 68 pharmacodynamic 68 cannabinor 68 Allovectin 7 R 68 antitumor activity 68 ixabepilone 68 RG# [001] 68 IAP inhibitor 68 receptor tyrosine kinase inhibitor 68 cMET 68 Azixa 68 selective androgen receptor modulator 68 fosbretabulin 68 vorinostat 68 investigational humanized monoclonal antibody 68 huC# DM4 68 Blinatumomab 68 Factor VIIa 68 DXL# 68 phase IIa clinical 68 MDV# 68 Cloretazine 68 targeting CD# 68 ponatinib 68 Bezielle 68 S/GSK# 68 Ceflatonin 68 mertansine 68 trabectedin 67 JAK1 67 HDAC Inhibitor 67 ATL# [001] 67 PS# [001] 67 Phase IIIb clinical 67 immunomodulatory 67 Pimavanserin 67 PRTX 67 Hsp# inhibition 67 LEP ETU 67 vandetanib 67 EFAPROXYN 67 amrubicin 67 DAVANAT 67 nab paclitaxel 67 tremelimumab 67 HspE7 67 Onconase 67 refractory CLL 67 TELINTRA 67 eprotirome 67 Phenoptin 67 Annamycin 67 ISIS # 67 Panzem 67 palifosfamide 67 SNT MC# 67 IL# PE#QQR 67 torezolid phosphate 67 PSN# [002] 67 Antiangiogenic 67 MGCD# [002] 67 pharmacodynamic PD 67 HQK 67 Cethrin 67 teriflunomide 67 Phase Ib II 67 XL# XL# 67 PDX pralatrexate 67 small molecule defensin 67 JAK2 inhibitor 67 ON #.Na 67 hematologic malignancies 67 ASA# 67 incyclinide 67 OMP #M# 67 HSP# inhibitor 67 urocortin 2 67 preclinical studies 67 Aplidin 67 Phase 1b 67 varespladib 67 phase IIb trial 67 kinase inhibitor 67 AeroLEF TM 67 ZYBRESTAT 67 GAP #B# 67 ISTODAX 67 CoFactor 67 IMC #B 67 PI3K/Akt pathway inhibitor 67 relapsed multiple myeloma 67 AZD# 67 thalidomide Thalomid 67 OvaRex R 67 adecatumumab 67 nonclinical studies 67 tivozanib 67 pharmacodynamic effects 67 antiangiogenic 67 Personalized Immunotherapy 67 TOCOSOL Paclitaxel 67 safety tolerability pharmacokinetic 66 NEUMUNE 66 Panzem R 66 iSONEP 66 NEUVENGE 66 CYT# potent vascular disrupting 66 novel anticancer 66 Tamibarotene 66 Seliciclib 66 EGFR inhibitors 66 CD# CEA 66 #ME# 66 Exherin TM 66 EOquin TM 66 oral ridaforolimus 66 AVN# [001] 66 BNC# 66 visilizumab 66 tubulin inhibitor 66 carfilzomib 66 orally bioavailable 66 glufosfamide 66 Azedra TM 66 PDE4 inhibitor 66 Phase Ib clinical trials 66 proteasome inhibitor 66 Phase IIa trials 66 Phase IIB 66 Androxal TM 66 CD# antibody [001] 66 registrational trial 66 custirsen 66 Plicera 66 bendamustine 66 CORT # 66 isavuconazole 66 relapsed refractory multiple myeloma 66 linaclotide 66 sunitinib malate 66 systemically administered 66 regorafenib 66 microtubule targeting 66 Aurora kinase 66 panobinostat 66 KRN# 66 T DM1 66 trastuzumab Herceptin R 66 LymphoStat B 66 Pemetrexed 66 OncoVEX 66 Allovectin 7 ® 66 metastatic RCC 66 cancer immunotherapies 66 investigational monoclonal antibody 66 selective modulator 66 SCH # 66 Zolinza 66 ocrelizumab 66 Guanilib 66 BIBW 66 Exelixis XL# 66 glatiramer acetate 66 rNAPc2 66 orally administered inhibitor 66 sorafenib Nexavar 66 blinatumomab 66 ZK EPO 66 Phase #b/#a clinical 66 heavily pretreated 66 HCV protease 66 Synavive 66 registrational 66 pradefovir 66 APTIVUS r 66 pan HDAC inhibitor 66 Phase #b/#a 66 talabostat 66 Phase 2a 66 AEGR 66 metaglidasen 66 ruxolitinib 66 GLYX 66 AKT inhibitor 66 Thiovir 66 EndoTAG TM -1 66 refractory multiple myeloma 66 immunomodulator 66 Viprinex 66 Telintra 66 ENMD 66 preclinical efficacy 66 Tarvacin TM 66 MOZOBIL 66 CTAP# Capsules 66 PLK1 SNALP 66 hematological malignancies 66 Enzastaurin 66 docetaxel Taxotere R 66 myeloproliferative disorders 66 Serdaxin 66 Omacetaxine 66 MLN# 66 xenograft models 66 Epothilones 66 pharmacodynamic profile 66 anti angiogenic 66 Phase IIa trial 66 ZOLINZA 66 PCK# 66 VEGF inhibitors 66 crizotinib PF # 66 panitumumab Vectibix 66 ADI PEG 66 PLX# 66 PEG PAL 66 Octreolin 66 GSK# [001] 66 Lenocta 66 #I TM# 66 Nanobody 66 Amrubicin 65 histone deacetylase HDAC inhibitor 65 gefitinib Iressa 65 TELCYTA 65 Stedivaze 65 Hsp# Inhibitor 65 Voreloxin 65 JAK2 inhibitors 65 tyrosine kinase inhibitor 65 hematological cancers 65 lumiliximab 65 VAPRISOL 65 posaconazole 65 dose escalation Phase 65 antibody MAb 65 novel VDA molecule 65 bortezomib 65 anticancer therapy 65 azacitidine 65 ILLUMINATE 65 molecularly targeted 65 Aplidin R 65 subcutaneous formulation 65 Tasimelteon 65 ONCONASE 65 Squalamine 65 Marqibo 65 PEP# [003] 65 FOLOTYN 65 Valortim 65 initiate Phase 1b 65 phase IIb 65 TRV# [001] 65 HCV protease inhibitors 65 Vilazodone 65 multitargeted 65 PEGylated interferon beta 1a 65 CDK inhibitor 65 HRPC 65 ostarine 65 TREANDA 65 PSMA ADC 65 dirucotide 65 HDAC inhibitors 65 TOLAMBA 65 iniparib 65 Aflibercept 65 Abiraterone acetate 65 RDEA# 65 IL #E 65 viral kinetics 65 tipifarnib 65 XL# XL# XL# XL# 65 Sapacitabine 65 teduglutide 65 celgosivir 65 TLK# 65 JAK3 65 Zybrestat 65 afatinib 65 EGFR HER2 65 dasatinib Sprycel 65 Amigal 65 sorafenib 65 Phase IIb trials 65 bortezomib Velcade 65 UPLYSO 65 gefitinib 65 lymphoid malignancies 65 Preclinical studies suggest 65 Belinostat 65 CTCE 65 Glufosfamide 65 Phase #/#a trial 65 apoptosis inducer 65 virus HCV protease inhibitor 65 sunitinib 65 Troxatyl 65 BZL# 65 sorafenib tablets 65 ALN VSP 65 RSD# oral 65 menadione 65 polymerase inhibitors 65 Hsp# inhibitor 65 pharmacodynamic properties 65 IRX 2 65 mGluR2 NAM 65 ProLindac 65 Cloretazine ® 65 CCR9 antagonist 65 MORAb 65 triphendiol 65 CIMZIA TM 65 PROSTVAC TM 65 CD# monoclonal antibody 65 TYKERB 65 HDAC inhibitor 65 Phase 2b Clinical Trial 65 anticancer activity 65 R roscovitine 65 thymalfasin 65 angiogenesis inhibitor 65 BCX# 65 CD3 monoclonal antibody 65 HCV protease inhibitor 65 Phase IIb clinical trials 65 Quinamed 65 humanized anti 65 PRX # 65 Apaziquone 65 veltuzumab 65 abiraterone acetate 65 pharmacokinetic interactions 65 imatinib Gleevec 65 motesanib 65 Alzhemed TM 65 XL# XL# XL# 65 aflibercept 65 OHR/AVR# 65 pharmacodynamic markers 65 pharmacokinetic PK 65 CUDC 65 SERMs 65 Tezampanel 65 Ophena TM 65 methylnaltrexone 65 Cloretazine R 65 adecatumumab MT# 65 erlotinib Tarceva 65 Tanespimycin 65 brostallicin 65 EOquin 65 anticancer agents 65 antiangiogenic therapy 65 cell lymphoma CTCL 65 myeloproliferative diseases 65 Proxinium TM 65 Tarvacin 65 Pazopanib 65 TKM ApoB 65 corticosteroid dexamethasone 65 tezampanel NGX# 65 ganaxolone 65 ataluren 65 histone deacetylase inhibitor 65 phase IIa 65 rBChE 65 ACZ# 65 anticancer therapies 65 MYDICAR ® 65 hypoxia activated prodrug 65 Amplimexon 65 AZILECT R 64 SRT# [003] 64 IMiDs 64 CIMZIA ™ 64 Insegia 64 oral mTOR inhibitor 64 APTIVUS 64 INSPIRE Trial Phase III 64 IIa trial 64 proteasome inhibitors 64 trastuzumab DM1 T DM1 64 ZD# [001] 64 #D#C# 64 chemotherapeutic agents 64 OMAPRO 64 Nuvion 64 Fx #A 64 Entereg R 64 CEQ# 64 tocilizumab 64 TORISEL 64 confirmatory Phase III 64 Apoptone 64 PARP inhibitor 64 Valortim R 64 Ostarine 64 antitumor effects 64 OvaRex ® MAb 64 Phase 2b trial 64 PI3K inhibitor 64 LibiGel ® 64 Leukine 64 BRIM2 64 novel peptide 64 Ocrelizumab 64 CINTREDEKIN BESUDOTOX 64 eculizumab 64 TG# [003] 64 L BLP# 64 PNP inhibitor 64 docetaxel Taxotere ® 64 Reolysin 64 brivaracetam 64 denufosol 64 MEND CABG II 64 Immunotherapeutic 64 radiation sensitizer 64 Curaxin 64 DermaVir Patch 64 ZACTIMA 64 uric acid lowering 64 NP2 Enkephalin 64 squalamine 64 bevacizumab Avastin ® 64 Fibrillex TM 64 daclizumab 64 tasimelteon 64 Metastatic Melanoma 64 mitogen activated ERK kinase 64 Dasatinib 64 non nucleoside HCV 64 delta isoform 64 olaparib 64 oxidative stress inducer 64 tolerability profiles 64 BiTE antibodies 64 ProSavin 64 Cotara 64 Ozarelix 64 Preclinical studies 64 chemopreventive agent 64 mycophenolate mofetil 64 oral antiviral 64 ARIKACE ™ 64 Xcytrin 64 bavituximab 64 generation Hsp# inhibitor 64 EGFr 64 ImmunoVEX HSV2 64 Fludara 64 tolerability pharmacokinetics 64 MNTX 64 bicifadine 64 GLP toxicology studies 64 antitumor efficacy 64 Saforis 64 LY# [002] 64 Interferon alpha 64 SinuNase 64 DOS# 64 antiangiogenic agents 64 ADAGIO study 64 delafloxacin 64 evaluating tivozanib 64 Vandetanib 64 satraplatin 64 epothilone 64 phase 2a 64 masitinib 64 isoform selective 64 Vidaza azacitidine 64 immunomodulatory effects 64 Tarceva TM 64 radiolabeled TM# 64 Natalizumab 64 refractory chronic lymphocytic 64 Antitumor Activity 64 AZILECT ® 64 trastuzumab DM1 64 Alocrest 64 generation NNRTI 64 picoplatin 64 TLR9 agonists 64 Genz # 64 cariprazine 64 rindopepimut 64 dose escalation 64 NXL# 64 OPAXIO 64 selective inhibition 64 Elotuzumab 64 liposomal formulation 64 MAXY G# 64 indibulin 64 bardoxolone 64 heavily pretreated patients 64 anti EGFR antibody 64 Vidofludimus 64 tesetaxel 64 Granulocyte Colony Stimulating Factor 64 FavId 64 GRN# 64 telomerase therapeutic 64 kinase inhibitors 64 Trofex 64 dexanabinol 64 ularitide 64 leukemia AML 64 HDACi 64 Hsp# inhibitors 64 TriRima 64 Zenvia ™ 64 PROMACTA 64 FGFR 64 Phenserine 64 PREOS 64 CINOD 64 antitumour activity 64 anti fibrotic 64 ThermoDox R 64 trodusquemine 64 nitazoxanide 64 hedgehog pathway 64 samalizumab 64 GMX# 64 trastuzumab Herceptin 64 solithromycin 64 metastatic castration resistant 64 octreotide implant 64 solid tumors 64 erythropoietic 64 dextromethorphan quinidine 64 Virulizin R 64 Aurora kinase inhibitors 64 Phase IIb III 64 SPRYCEL ® 64 TMC# [002] 64 RH1 64 taxanes 63 anti angiogenic agents 63 INT# [002] 63 VEGF Trap 63 DACH platinum 63 investigational compound 63 urate lowering 63 temsirolimus 63 cutaneous T cell 63 Aurora kinase inhibitor 63 Viramidine 63 PEGPH# 63 beta 1a 63 randomized Phase 2b 63 pharmacokinetics pharmacodynamics 63 davunetide intranasal AL 63 radezolid 63 relapsed ovarian cancer 63 relapsed SCLC 63 ALN RSV# 63 Bendavia 63 TYZEKA 63 ThGRF 63 castration resistant prostate cancer 63 tolerability 63 lupus nephritis 63 farletuzumab 63 ridaforolimus 63 SARMs 63 alkylating agent 63 bafetinib 63 anti amnesic 63 bosutinib 63 SUTENT 63 clofarabine 63 ALN TTR 63 refractory CTCL 63 cetuximab Erbitux 63 ZYBRESTAT fosbretabulin 63 pegylated interferons 63 nucleoside analog 63 lorvotuzumab mertansine 63 pro angiogenic 63 panitumumab 63 sulodexide 63 placebo controlled clinical 63 cetuximab Erbitux ® 63 LEUKINE 63 Zerenex 63 cytoprotective 63 TPI ASM8 63 ELND# 63 sipuleucel T 63 Chemophase 63 Icatibant 63 Phase 2b study 63 darapladib 63 FTY# 63 randomized discontinuation trial 63 interferon gamma 1b 63 huN# DM1 63 multicenter Phase II 63 antiangiogenic activity 63 LUX Lung 63 imatinib Gleevec ® 63 Enzyme Replacement Therapy 63 potent anticancer 63 nalbuphine ER 63 DAVANAT ® 63 investigational compounds 63 maximally tolerated dose 63 tipranavir 63 Velcade bortezomib 63 potent antiproliferative 63 Vorinostat 63 fibrotic disease 63 Aurora Kinase 63 imatinib therapy 63 Phase 2a clinical 63 rFIXFc 63 rituximab 63 Revlimid lenalidomide 63 lesinurad 63 Antiviral Activity 63 HDAC inhibition 63 tgAAC# 63 metastatic renal cell carcinoma 63 Darinaparsin 63 brentuximab vedotin 63 Phase #b/#a trial 63 pemetrexed 63 bosentan 63 tolerability profile 63 ARIKACE 63 PANVAC VF 63 CLORETAZINE TM VNP#M 63 VEGF receptor 63 mTOR inhibition 63 Asentar 63 TKB# 63 FOLFOX6 chemotherapy regimen 63 NEUGENE 63 Cutaneous T 63 docetaxel chemotherapy 63 teplizumab 63 lomitapide 63 TRAIL receptor antibodies 63 standard chemotherapy regimens 63 tafamidis 63 trastuzumab Herceptin ® 63 Trastuzumab 63 PARP inhibitors 63 laquinimod 63 viral kinetic 63 antithrombotic 63 Neulasta ® 63 GAMMAGARD 63 resolvins 63 orally dosed 63 MBP# [001] 63 multicenter Phase 63 AMD# [003] 63 generation proteasome inhibitor 63 vilazodone 63 INC# 63 OMP #R# 63 calcineurin inhibitors 63 dasatinib 63 protein kinase inhibitor 63 thrombopoietin 63 refractory AML 63 unique alkylating agent 63 oral methylnaltrexone 63 oral picoplatin 63 refractory gout 63 LymphoStat B TM 63 LAF# 63 antiviral efficacy 63 fibrinolytic 63 oxymorphone ER 63 ongoing Phase 1b 63 deacetylase inhibitors 63 ANG# 63 Taxotere ® 63 Dapagliflozin 63 Talabostat 63 Homspera 63 EpCAM 63 tamibarotene 63 Panzem NCD 63 liposomal doxorubicin 63 seliciclib CYC# 63 ARRY 63 cetuximab Erbitux R 63 Aclidinium 63 mGluR5 NAM 63 AVE# 63 CCR5 antagonist 63 synthetic retinoid 63 ThermoDox ® clinical 63 peripherally acting 63 PROCHYMAL 63 Marqibo TM 63 preclinical models 63 NNR Therapeutics 63 Ixempra 63 Randomized Phase 63 PF # [001] 63 Pivotal Phase III 63 non nucleoside inhibitor 63 Lu AA# 63 insulin sensitizing 63 gemcitabine Gemzar ® 63 standard chemotherapy regimen 63 anticancer compound 63 ADVEXIN 63 Omacetaxine mepesuccinate 63 Tavocept 63 advanced carcinoid 63 Initiate Phase 63 VELCADE melphalan 63 Nanobody ® 63 preclinical 63 CRx 63 UVIDEM 63 Tarceva erlotinib 63 recurrent GBM 63 immune modulating 63 low dose cytarabine 63 AAG geldanamycin analog 63 ALN PCS 63 rilonacept 63 Pertuzumab 63 investigational therapies 63 Phase 2b clinical 63 CORLUX CORT # 63 EGFR tyrosine kinase inhibitors 63 phase IIb study 63 anticoagulant reversing agent 63 HIF PHI 63 biologic therapy 63 telaprevir VX 63 RNAi therapeutic targeting 63 sunitinib Sutent ® 63 EndoTAGTM 1 63 epothilones 63 Valortim ® 63 volociximab 62 MMP inhibitors 62 tramiprosate 62 Phase IIa clinical 62 Phase 1b clinical trials 62 Protexia ® 62 immunomodulating 62 DU #b 62 CBLB# 62 GRNVAC1 62 ONTAK 62 Vitaxin 62 Gleevec resistant 62 pharmacodynamic parameters 62 somatostatin analogues 62 lapatinib Tykerb 62 recurrent glioblastoma multiforme 62 metastatic CRC 62 Akt inhibitor 62 dexpramipexole 62 oral deforolimus 62 dose escalation trial 62 therapeutic regimens 62 LE DT 62 adipiplon 62 elagolix 62 IMP# 62 bevacizumab Avastin 62 Inhalation Solution 62 gemcitabine 62 cytokine refractory 62 anti proliferative 62 MERLIN TIMI 62 relapsed MM 62 EP #R 62 Cethrin R 62 vicriviroc 62 INGN 62 R sorafenib tablets 62 ATL/TV# 62 leukemia CLL 62 ISENTRESS 62 partial agonist 62 EZN 62 CB2 selective receptor agonist 62 Denufosol 62 hA# 62 CRMD# 62 Anti Tumor 62 INCB# [003] 62 novel topoisomerase 62 GGF2 62 relapsing multiple sclerosis 62 APPRAISE 62 NEUGENE antisense 62 class mGluR5 inhibitor 62 immune modulatory 62 fluoropyrimidine 62 LymphoStat B belimumab 62 refractory metastatic 62 recurrent glioblastoma 62 novel histone deacetylase 62 Talactoferrin 62 Aliskiren 62 CCR2 62 Phase 1a clinical 62 Phase IIa 62 Zoraxel 62 CaPre TM 62 estramustine 62 PROSTVAC VF 62 oral Azacitidine 62 Capesaris 62 TBC# 62 midstage clinical 62 Hedgehog antagonist 62 secretory phospholipase A2 sPLA2 62 TroVax 62 SILENOR TM 62 Clolar ® 62 candidate CRLX# 62 Nexavar ® 62 FOLFOX chemotherapy 62 antiviral activity 62 dose cohorts 62 potent antiviral 62 CIMZIA TM certolizumab pegol 62 Romiplostim 62 SAR# [002] 62 kinase inhibition 62 reslizumab 62 elvucitabine 62 CDK inhibitors 62 ozarelix 62 glucagon receptor 62 Indibulin 62 TroVax ® 62 TRISENOX 62 Aviptadil

Back to home page